Receptor News and Research

RSS

Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease

Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease.

1 Feb 2010

New biomarker may predict treatment outcomes in RA patients

Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.

30 Jan 2010

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

30 Jan 2010

New study identifies that SynDIG1 plays critical role in creating and sustaining synapses

A new study from UC Davis Health System identifies for the first time a brain protein called SynDIG1 that plays a critical role in creating and sustaining synapses, the complex chemical signaling system responsible for communication between neurons.

30 Jan 2010

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer.

29 Jan 2010

BBVA Foundation Frontiers of Knowledge Award granted to Robert J. Lefkowitz

The BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category goes in this second edition to Prof. Robert J. Lefkowitz (1943, New York, United States), investigator in the Department of Medicine at Duke University (United States).

29 Jan 2010

Econiche vaccine cited in February, 2010 issue of Scientific American

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that Econiche(TM), the world's first vaccine developed to reduce the shedding by cattle of Escherichia coli (E. coli) O157, has been cited in the February, 2010 issue of Scientific American (Vol. 302, # 2).

29 Jan 2010

New understanding of CD44 receptor's role in immune cell survival

Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a new way the cell surface protein, CD44, helps specific T helper (Th1) cells develop immunologic memory.

29 Jan 2010

Study sheds light on pancreatic cancer development and new potential drug targets

Researchers at the Moores Cancer Center at the University of California, San Diego, have found one reason that pancreatic cancer tumors are so difficult to treat with drugs. They have shown how a molecular switch steps up pancreatic cancer cell survival as well as resistance to a standard chemotherapy drug, and have identified alternate routes cancer cells take to avoid the effects of the therapy.

29 Jan 2010

Researchers discover new target for drugs to prevent common iron deficiency

The discovery of a major player in the body's regulation of iron levels should provide a new target for drugs that prevent common iron deficiency as well as rare, potentially deadly iron overload, researchers said.

29 Jan 2010

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

NIDA supports Omeros' Addiction program

Omeros Corporation today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company's Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be conducted by New York State Psychiatric Institute researchers.

28 Jan 2010

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.

28 Jan 2010

Blocking action of key protein boosts immune 'memory' to prevent or clear viral infection

Researchers at The Scripps Research Institute have discovered a potential new way to stimulate the immune system to prevent or clear a viral infection. By blocking the action of a key protein in the mouse immune system, they were able to boost immune "memory" in those mice-work that may one day help doctors increase the effectiveness of human vaccines designed to prevent viral infections.

28 Jan 2010

Seroquel XR's FDA approval does not change Decision Resources' earlier antipsychotics market forecast

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the recent decision by the U.S. Food and Drug Administration (FDA) to grant approval of AstraZeneca's Seroquel XR for adjunctive treatment of major depressive disorder will not change Decision Resources' market forecast for the indication. As previously forecasted, Seroquel and Seroquel XR will garner nearly one quarter of antipsychotics sales as adjunctive treatments for major depressive disorder in 2013 in the world's major pharmaceutical markets.

28 Jan 2010

IRSF announces first 2010 ANGEL Grant for testing potential Rett Syndrome therapies

Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.

28 Jan 2010

Case Western Reserve University School of Medicine awarded 6 DOD CDMRP grants for medical research

Case Western Reserve University School of Medicine has been awarded six Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP) grants for innovative medical research. The grants, totaling nearly $2.8 million, will advance research in the field of breast cancer.

28 Jan 2010

Good bacteria may help counteract negative effects of antibiotics in humans

Scientists have long pondered the seeming contradiction that taking broad-spectrum antibiotics over a long period of time can lead to severe secondary bacterial infections. Now researchers from the University of Pennsylvania School of Medicine may have figured out why.

27 Jan 2010

Two new studies further the understanding of molecular steps in PLC cascade

Two new studies by researchers at the University of Washington further our understanding of the molecular steps in the PLC cascade, a G protein-coupled receptor signaling mechanism that underlies a wide variety of cellular processes, including egg fertilization, hormone secretion, and the regulation of certain potassium channels.

27 Jan 2010

Receptor News and Research

Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease

New biomarker may predict treatment outcomes in RA patients

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

New study identifies that SynDIG1 plays critical role in creating and sustaining synapses

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

BBVA Foundation Frontiers of Knowledge Award granted to Robert J. Lefkowitz

Econiche vaccine cited in February, 2010 issue of Scientific American

New understanding of CD44 receptor's role in immune cell survival

Study sheds light on pancreatic cancer development and new potential drug targets

Researchers discover new target for drugs to prevent common iron deficiency

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

Ligand Pharmaceuticals acquires Metabasis Therapeutics

NIDA supports Omeros' Addiction program

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Blocking action of key protein boosts immune 'memory' to prevent or clear viral infection

Seroquel XR's FDA approval does not change Decision Resources' earlier antipsychotics market forecast

IRSF announces first 2010 ANGEL Grant for testing potential Rett Syndrome therapies

Case Western Reserve University School of Medicine awarded 6 DOD CDMRP grants for medical research

Good bacteria may help counteract negative effects of antibiotics in humans

Two new studies further the understanding of molecular steps in PLC cascade

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News